Posted by Sarah Showard | Jul 28, 2016 | 0 Comments

The development of the Taxane family of cancer drugs started in the 1960's with the United States' discovery of a molecule from the Pacific Yew Tree. This tree possessed a molecule which prevented the division of cancer cells by freezing the cell division process. From this point stemmed the development of a chemotherapy drug called Taxol which was developed by the company Bristol Myers. However, in order to compete with Taxol, Sanofi-Aventis, a French company, developed a synthetic form of this drug, called Taxotere, which has more potent side- effects and is less effective than Taxol. Taxotere received FDA approval in 1996 and began marketing their drug as more effective than Taxol because a less frequent dose was required. Taxotere was then used to treat breast cancer patients, especially patients with recalcitrant forms of breast cancer. However, it was found that over time, patients who had been treated with Taxotere ended up with


permanent hair loss, or alopecia. At this time, neither the oncologists prescribing the drug, nor the patients, were aware of this side-effect. It was revealed much later that Sanofi-Aventis was aware of this side-effect, but refused to publicize it because they feared it would adversely affect their market shares. It was not until January of 2016, 20 years after the product was approved, that the company labeled the product with the alopecia side-effect. As a result, doctors and patients were not given the choice to use Taxol, which does not cause permanent hair loss. In a study conducted by the Consumer Attorney Marketing Group, it was found that 8% of women would have resisted life-saving cancer treatment if it meant they would not lose their hair, even if it was temporary hair loss. These women must now go about their daily lives with the stigma of being a cancer patient, and they must deal with the adversities which come with permanent baldness.

About the Author

Sarah Showard

Sarah Showard graduated from the University of Maryland in 1985, Magna Cum Laude with a Bachelor of Arts in English-Linguistics and a Certification in Women's Studies. She then graduated from New York University School of Law in 1988. Sarah began practice initially as an insurance defense attorney, and has been representing plaintiffs since 1990. Sarah has a son, Benjamin, who recently graduated from The Gregory School and will attend ASU in the fall, with future plans to attend law school and eventually join Showard Law Firm. In her spare time Sarah enjoys horseback riding and spending time in Sonoita with her husband Peter.


There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Showard Law Firm-Tucson's Local Law Firm for defective drug & medical device claims.

Showard law firm group photo compressor

Showard Law Firm is dedicated to compassionate representation for our clients who have been injured by defective products, dangerous drugs or the negligence of any individual or company. We are experienced in litigation and ready to ensure you receive the maximum possible settlement for your injuries, medical bills, mental anguish and other losses.

Showard Law Firm celebrates 10 years

10th anniversary showard

2016 marked the 10th anniversary of Showard Law Firm. After 18 years of practice, and a prior ten-year partnership, Sarah Showard and her longtime assistant, Maria De La Rosa, opened the doors of Showard Law Firm in October 2006. Sarah and everyone at Showard Law Firm is proud to serve Southern Arizona as the local law firm for defective drug and medical device claims and personal injury.